Kite (pharma)

from Wikipedia, the free encyclopedia

Kite Pharma is a US-American biopharmaceutical drug company engaged in the development of innovative cancer immunotherapies (including CAR-T-cell therapy ). The first gene therapy product approved in the USA and the EU : Axicabtagene Ciloleucel (trade name: Yescarta ).

In October 2017, Gilead Sciences announced it had acquired Kite Pharma for just under $ 12 billion.

Kite is headquartered in Santa Monica , California . The European branches are located in an industrial park in Heathrow near London and Amsterdam .

Corporate background

The company focuses on cell therapies with chimeric antigen receptors (CAR) and T-cell receptors (TCR), which aim to strengthen the immune system's ability to recognize and kill tumors. Kite develops artificial cell therapies that express either a chimeric antigen receptor (CAR) or a T cell receptor (TCR), depending on the type of cancer. Kite's platform has the potential to combat both hematological and solid cancers.

Products

  • Axicabtagene Ciloleucel ( Yescarta ) was approved by the US FDA in October 2017 for the treatment of patients with relapsed or refractory aggressive non-Hodgkin lymphoma who are not eligible for an autologous stem cell transplant . European approval took place in August 2018.
  • Kite and Gilead Sciences have numerous product candidates in the pipeline. The indication areas include viral diseases (e.g. AIDS, Ebola, etc.), inflammatory diseases ( rheumatoid arthritis , ulcerative colitis , Crohn's disease, etc.) and various types of cancer.

Cooperations

  • In April 2020, Gilead Sciences, Kite and oNKo-innate announce a research collaboration to discover cancer immunotherapies with a focus on natural killer cells (NK).
  • Kite and the US pharmaceutical company Amgen are collaborating in the research and development of new CAR T cell therapies.
  • Kite and the Chinese pharmaceutical company Fosun Pharma founded Fosun Kite , a joint venture to develop, manufacture and commercialize axicabtagen ciloleucel in China - with the option to add additional products, including two TCR product candidates from Kite.

See also

Web links

Individual evidence

  1. ↑ YESCARTA (axicabtagene ciloleucel) , FDA, Approved Cellular and Gene Therapy Products, accessed April 28, 2020
  2. ↑ Yescarta , EPAR of the EMA, accessed on April 28, 2020
  3. ↑ Overview of Yescarta and justification for approval in the EU , EMA (German), accessed on April 28, 2020
  4. ↑ Gilead Sciences Completes Acquisition of Kite Pharma, Inc. , Gilead PM, October 3, 2017, accessed April 25, 2020
  5. ↑ Kite Locations , company website, accessed April 25, 2020
  6. ^ One Mission, Two Platforms , company website, accessed April 25, 2020
  7. ↑ Kite's Yescarta ™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy , PM Gilead, October 18, 2017 on April 25, 2020
  8. ↑ Yescarta® (Axicabtagene Ciloleucel) Receives European Marketing Authorization , PM Gilead, August 27, 2018, accessed April 25, 2020
  9. ↑ Yescarta Axicabtagene Ciloleucel , EPAR of the EMA, accessed on April 25, 2020
  10. ^ Pipeline , Gilead Sciences website, accessed April 25, 2020
  11. ↑ Gilead, Kite and onKo-innate Announce Research Collaboration to Discover Cancer Immunotherapies Focused on Natural Killer (NK) Cells , PM Gilead, April 21, 2020, accessed April 25, 2020
  12. ↑ a b Collaborations , company website, accessed April 25, 2020